Walleye Capital LLC trimmed its holdings in Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) by 18.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,908 shares of the company’s stock after selling 11,563 shares during the period. Walleye Capital LLC’s holdings in Century Therapeutics were worth $641,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently modified their holdings of IPSC. American International Group Inc. boosted its holdings in shares of Century Therapeutics by 37.1% in the first quarter. American International Group Inc. now owns 8,604 shares of the company’s stock valued at $108,000 after buying an additional 2,328 shares during the period. MetLife Investment Management LLC acquired a new position in Century Therapeutics in the 1st quarter worth $153,000. New York State Common Retirement Fund increased its holdings in Century Therapeutics by 76.9% during the 1st quarter. New York State Common Retirement Fund now owns 13,651 shares of the company’s stock worth $172,000 after purchasing an additional 5,933 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Century Therapeutics in the 1st quarter valued at about $188,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Century Therapeutics by 11.2% during the first quarter. Goldman Sachs Group Inc. now owns 20,746 shares of the company’s stock worth $261,000 after buying an additional 2,091 shares during the period. 36.97% of the stock is currently owned by institutional investors.
In related news, major shareholder Versant Venture Capital Vi, L. sold 550,000 shares of the business’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $13.03, for a total transaction of $7,166,500.00. Following the transaction, the insider now directly owns 11,816,814 shares in the company, valued at $153,973,086.42. The sale was disclosed in a filing with the SEC, which is available through this link. 10.30% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Century Therapeutics Trading Down 2.4 %
Century Therapeutics stock opened at $9.41 on Thursday. The company has a market cap of $554.08 million, a price-to-earnings ratio of -4.90 and a beta of 0.27. The firm has a 50-day moving average of $10.87 and a 200-day moving average of $10.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 17.79 and a quick ratio of 17.79. Century Therapeutics, Inc. has a one year low of $7.32 and a one year high of $25.87.
Century Therapeutics (NASDAQ:IPSC – Get Rating) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.04). The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.20 million. On average, equities analysts expect that Century Therapeutics, Inc. will post -2.41 earnings per share for the current fiscal year.
Century Therapeutics Company Profile
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.